Telomere Therapeutics
PrivateLast Round
Accelerator
Dec 13, 2023
Total Funding Raised
$2.32M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Telomere Therapeutics operates in Healthcare & Life Sciences and is based in Barcelona. Its latest recorded funding round was an Accelerator round in December 2023.
Telomere Therapeutics is a gene therapy company developing disease modifying treatments for unmet medical needs, pioneering the repair of telomeres to treat organ fibrosis and other telomere-dysfunction syndromes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Telomere Therapeutics Comparables
Compare Telomere Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rejuvenation Technologies | 78% | |
| PureTech Health | 62% | |
| Roche Holding | 62% |
For institutional investors. Book with your work email.
Telomere Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Dec 13, 2023 | ||||
| Grant | Jan 1, 2022 | ||||
| Seed | May 25, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Telomere Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Arquimedes Accelerator | Accelerator |
| European Commission | Grant |
| Community of Madrid | Grant |
| Center for Technological Development and Innovation | Grant, Seed |
| Invivo Partners | Seed |
| NextGenerationEU | Grant |
| Santander Universities | Accelerator |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 67% MoM, reaching 1.8K.
- Jul 24, 2026
Monthly visitors grew 233% MoM, reaching 1.1K.
For institutional investors. Book with your work email.
Telomere Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Telomere Therapeutics's valuation, stock price, and market status.
Is Telomere Therapeutics a public or private company?
Telomere Therapeutics is a private company.
What is the current stock price of Telomere Therapeutics?
Telomere Therapeutics is a private company, so its shares have no public market price. Caplight tracks Telomere Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Telomere Therapeutics worth (valuation)?
Valuation information for Telomere Therapeutics is not publicly available.
Can I buy Telomere Therapeutics stock?
Telomere Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Telomere Therapeutics's last funding round?
Telomere Therapeutics's most recent funding round was Accelerator on December 13, 2023.
Who are the main investors in Telomere Therapeutics?
Key investors in Telomere Therapeutics include Invivo Partners.
Will Telomere Therapeutics IPO soon?
No public IPO plans have been announced for Telomere Therapeutics.
How can I track Telomere Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Telomere Therapeutics's shares on secondary markets.